Hereditary Angioedema

Company announces results from two clinical trials of DX-88

Published in Hepatitis Weekly, August 1st, 2005

Dyax Corp. (DYAX) announced positive top-line results from its completed phase I trial to evaluate safety and pharmacokinetics (PK) of subcutaneously administered DX-88 in normal volunteers.

The company also announced the presentation at the World Allergy Congress in Munich, Germany of positive interim results from the first 120 attacks of hereditary angioedema (HAE) treated with intravenously administered DX-88 in its open-label, repeat-dosing, phase II trial referred to as EDEMA2. DX-88 is being developed in a joint venture with Genzyme Corp. for the treatment of HAE, a debilitating and life-threatening inflammatory condition characterized by unpredictable attacks of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry